Buh-bye Aduhelm. "Biogen said it will end development and commercialization of its controversial Alzheimer’s drug Aduhelm, which was approved against outside experts’ advice in mid-2021 and caused congressional inquiries and broader market pushback on pricing and efficacy......this essentially discontinues the drug."

https://endpts.com/biogen-to-halt-sales-and-d...g-aduhelm/

I guess maybe people didn't want to pay a quarter of a million dollars a year for a drug that causes brain breeds and doesn't help much, if at all.